Inactive Ingredient Search for Approved Drug Products
Search Names Beginning with I
Inactive Ingredient | Route | Dosage Form | CAS Number | UNII | Maximum Potency per unit dose | Maximum Daily Exposure (MDE) | Record Updated |
---|---|---|---|---|---|---|---|
ICODEXTRIN | ORAL | TABLET | 337376155 | 2NX48Z0A9G | 8mg | ||
ICODEXTRIN | ORAL | TABLET, COATED | 337376155 | 2NX48Z0A9G | 10mg | ||
ICODEXTRIN | ORAL | TABLET, DELAYED RELEASE | 337376155 | 2NX48Z0A9G | 9.25mg | ||
ICODEXTRIN | ORAL | TABLET, EXTENDED RELEASE | 337376155 | 2NX48Z0A9G | 6mg | ||
ICODEXTRIN | TOPICAL | CREAM | 337376155 | 2NX48Z0A9G | 0.03%w/w | ||
ICODEXTRIN | TOPICAL | LOTION | 337376155 | 2NX48Z0A9G | NA | ||
ICODEXTRIN | TOPICAL | SHAMPOO | 337376155 | 2NX48Z0A9G | 5%w/w | ||
IMIDUREA | TOPICAL | CREAM | 39236469 | M629807ATL | 0.4%w/w | ||
IMIDUREA | TOPICAL | LOTION | 39236469 | M629807ATL | 228mg | ||
IMIDUREA | TOPICAL | SHAMPOO | 39236469 | M629807ATL | 0.4%w/w | ||
INDIGOTINDISULFONATE SODIUM | ORAL | CAPSULE | 860220 | D3741U8K7L | 0.68mg | ||
INDIGOTINDISULFONATE SODIUM | ORAL | TABLET, EXTENDED RELEASE | 860220 | D3741U8K7L | 0.04mg | ||
INK BLACK 2271 | ORAL | CAPSULE | NA | NA | |||
INK BLACK A-10464 | ORAL | TABLET, EXTENDED RELEASE | NA | NA | |||
INK BLACK A-10527 | ORAL | TABLET, EXTENDED RELEASE | NA | 0.19mg | |||
INK BLACK FGE-1386 | ORAL | CAPSULE | NA | NA | |||
INK BLACK SW-9007 | ORAL | TABLET | NA | 0.09mg | |||
INK BLACK SW-9007 | ORAL | TABLET, FILM COATED | NA | 0.09mg | |||
INK BLACK SW-9008 | NASAL | POWDER | NA | NA | |||
INK BLACK SW-9008 | ORAL | CAPSULE | NA | 1mg | |||
INK BLACK SW-9008 | ORAL | CAPSULE, COATED | NA | NA | |||
INK BLACK SW-9008 | ORAL | CAPSULE, DELAYED RELEASE | NA | 1mg | |||
INK BLACK SW-9008 | ORAL | CAPSULE, EXTENDED RELEASE | NA | 1mg | |||
INK BLACK SW-9009 | ORAL | CAPSULE | NA | NA | |||
INK BLUE TEK PRINT SB-6029 | ORAL | CAPSULE | NA | NA | |||
INK BLUE TEK PRINT SB-6029 | ORAL | TABLET, EXTENDED RELEASE | NA | 0.2mg | |||
INK BLUE TEKPRINT SB-6018 | ORAL | CAPSULE | NA | 0.22mg | |||
INK BLUE TEKPRINT SB-6018 | ORAL | CAPSULE, EXTENDED RELEASE | NA | 0.04mg | |||
INK EDIBLE BLACK | ORAL | CAPSULE | NA | 0.25mg | |||
INK EDIBLE BLACK | ORAL | TABLET | NA | 0.2mg | |||
INK EDIBLE BLACK | ORAL | TABLET, COATED | NA | 0.4mg | |||
INK EDIBLE BLACK | ORAL | TABLET, EXTENDED RELEASE | NA | 1mg | |||
INK EDIBLE BLUE | ORAL | CAPSULE | NA | 1mg | |||
INK EDIBLE BLUE | ORAL | TABLET | NA | NA | |||
INK EDIBLE BLUE | ORAL | TABLET, COATED | NA | 0.04mg | |||
INK EDIBLE BLUE | ORAL | TABLET, FILM COATED | NA | NA | |||
INK EDIBLE BROWN | ORAL | TABLET, COATED | NA | 0.04mg | |||
INK EDIBLE GRAY | ORAL | CAPSULE | NA | NA | |||
INK EDIBLE RED | ORAL | TABLET | NA | 0.01mg | |||
INK EDIBLE RED | ORAL | TABLET, COATED | NA | NA | |||
INK EDIBLE RED | ORAL | TABLET, DELAYED RELEASE | NA | NA | |||
INK EDIBLE WHITE | ORAL | CAPSULE | NA | NA | |||
INK EDIBLE WHITE | ORAL | CAPSULE, EXTENDED RELEASE | NA | 0.04mg | |||
INK EDIBLE WHITE | ORAL | TABLET, COATED | NA | NA | |||
INK EDIBLE WHITE | ORAL | TABLET, EXTENDED RELEASE | NA | 0.19mg | |||
INK EDIBLE WHITE | ORAL | TABLET, FILM COATED | NA | NA | |||
INK FINE BLACK 2212 | ORAL | TABLET | NA | NA | |||
INK FINE BLACK 2212 | ORAL | TABLET, EXTENDED RELEASE | NA | NA | |||
INK RED A-8032 | ORAL | CAPSULE | NA | NA | |||
INK RED A-8032 | ORAL | TABLET, COATED | NA | NA | |||
INK S-1-7085 | ORAL | CAPSULE | NA | NA | |||
INK WHITE A-8154 | ORAL | CAPSULE | NA | 0.8mg | |||
INK WHITE A-8154 | ORAL | TABLET | NA | NA | |||
INK WHITE SB-0007P | ORAL | CAPSULE | NA | 1mg | |||
INK WHITE SW-0012 | ORAL | CAPSULE | NA | NA | |||
INK WHITE SW-0012 | ORAL | CAPSULE, DELAYED RELEASE | NA | NA | |||
INK WHITE SW-0012 | ORAL | TABLET | NA | 0.2mg | |||
INVERT SUGAR | ORAL | CAPSULE | 8013170 | ED959S6ACY | NA | ||
INVERT SUGAR | ORAL | SOLUTION | 8013170 | ED959S6ACY | 3.06ml/5ml | ||
INVERT SUGAR | ORAL | SYRUP | 8013170 | ED959S6ACY | 2560mg/5ml | ||
IRON | ORAL | TABLET, EXTENDED RELEASE | 7439896 | E1UOL152H7 | 5mg | ||
ISOBUTANE | RECTAL | AEROSOL, FOAM | 75285 | BXR49TP611 | 142mg | ||
ISOBUTANE | TOPICAL | AEROSOL | 75285 | BXR49TP611 | 4484mg | ||
ISOBUTANE | TOPICAL | AEROSOL, FOAM | 75285 | BXR49TP611 | 18%w/w | ||
ISOBUTANE | TOPICAL | AEROSOL, SPRAY | 75285 | BXR49TP611 | 4484mg | ||
ISOLEUCINE | INTRAVENOUS | INJECTION | 73325 | 04Y7590D77 | 0.9%w/v | ||
ISOLEUCINE | INTRAVENOUS | INJECTION, SOLUTION | 73325 | 04Y7590D77 | 0.21%w/v | ||
ISOMALT | ORAL | CAPSULE | 64519820 | S870P55O2W | 73mg | ||
ISOMALT | ORAL | TABLET | 64519820 | S870P55O2W | 522mg | ||
ISOMALT | ORAL | TABLET, CHEWABLE | 64519820 | S870P55O2W | 630mg | ||
ISOMALT | ORAL | TROCHE | 64519820 | S870P55O2W | 1718.71mg | ||
ISOMALT | SUBLINGUAL | POWDER | 64519820 | S870P55O2W | 530mg | ||
ISOPROPYL ALCOHOL | TOPICAL | GEL | 67630 | ND2M416302 | 75mg | ||
ISOPROPYL ALCOHOL | TOPICAL | LOTION, AUGMENTED | 67630 | ND2M416302 | 30%w/w | ||
ISOPROPYL ALCOHOL | TOPICAL | OIL | 67630 | ND2M416302 | 72mg | ||
ISOPROPYL ALCOHOL | TOPICAL | SOLUTION | 67630 | ND2M416302 | 40%w/v | ||
ISOPROPYL ALCOHOL | TOPICAL | SPONGE | 67630 | ND2M416302 | 4%w/w | ||
ISOPROPYL ALCOHOL | TOPICAL | SWAB | 67630 | ND2M416302 | 43.9%w/w | ||
ISOPROPYL ISOSTEARATE | TOPICAL | CREAM | 68171335 | C67IXB9Y7T | 3%w/w | ||
ISOPROPYL MYRISTATE | AURICULAR (OTIC) | OIL | 110270 | 0RE8K4LNJS | 3.85%v/v | ||
ISOPROPYL MYRISTATE | AURICULAR (OTIC) | SUSPENSION | 110270 | 0RE8K4LNJS | 0.02%w/w | ||
ISOPROPYL MYRISTATE | TOPICAL | AEROSOL | 110270 | 0RE8K4LNJS | 9.3%w/w | ||
ISOPROPYL MYRISTATE | TOPICAL | AEROSOL, FOAM | 110270 | 0RE8K4LNJS | 144mg | ||
ISOPROPYL MYRISTATE | TOPICAL | AEROSOL, SPRAY | 110270 | 0RE8K4LNJS | 6.89%w/w | ||
ISOPROPYL MYRISTATE | TOPICAL | CREAM | 110270 | 0RE8K4LNJS | 800mg | ||
ISOPROPYL MYRISTATE | TOPICAL | CREAM, AUGMENTED | 110270 | 0RE8K4LNJS | 8%w/w | ||
ISOPROPYL MYRISTATE | TOPICAL | GEL | 110270 | 0RE8K4LNJS | 29mg | Y | |
ISOPROPYL MYRISTATE | TOPICAL | LOTION | 110270 | 0RE8K4LNJS | 5%w/w | ||
ISOPROPYL MYRISTATE | TOPICAL | OIL | 110270 | 0RE8K4LNJS | 213mg | ||
ISOPROPYL MYRISTATE | TOPICAL | OINTMENT | 110270 | 0RE8K4LNJS | 35%w/w | ||
ISOPROPYL MYRISTATE | TOPICAL | SPRAY | 110270 | 0RE8K4LNJS | 3665mg | ||
ISOPROPYL MYRISTATE | TOPICAL | SYSTEM | 110270 | 0RE8K4LNJS | 7mg | ||
ISOPROPYL MYRISTATE | TRANSDERMAL | FILM | 110270 | 0RE8K4LNJS | 58.08mg | ||
ISOPROPYL MYRISTATE | TRANSDERMAL | FILM, EXTENDED RELEASE | 110270 | 0RE8K4LNJS | 20.4mg | ||
ISOPROPYL MYRISTATE | TRANSDERMAL | GEL | 110270 | 0RE8K4LNJS | 50mg | ||
ISOPROPYL MYRISTATE | TRANSDERMAL | GEL, METERED | 110270 | 0RE8K4LNJS | 1%w/w | ||
ISOPROPYL MYRISTATE | TRANSDERMAL | SYSTEM | 110270 | 0RE8K4LNJS | 113mg | ||
ISOPROPYL MYRISTATE | VAGINAL | CREAM | 110270 | 0RE8K4LNJS | 1%w/w | ||
ISOPROPYL MYRISTATE | VAGINAL | SUPPOSITORY | 110270 | 0RE8K4LNJS | 0.01mg | ||
ISOPROPYL PALMITATE | TOPICAL | AEROSOL | 142916 | 8CRQ2TH63M | 397mg | ||
ISOPROPYL PALMITATE | TOPICAL | AEROSOL, SPRAY | 142916 | 8CRQ2TH63M | 397mg | ||
ISOPROPYL PALMITATE | TOPICAL | CREAM | 142916 | 8CRQ2TH63M | 112mg | ||
ISOPROPYL PALMITATE | TOPICAL | GEL | 142916 | 8CRQ2TH63M | NA | ||
ISOPROPYL PALMITATE | TOPICAL | LOTION | 142916 | 8CRQ2TH63M | 5%w/w | ||
ISOPROPYL PALMITATE | TOPICAL | OINTMENT | 142916 | 8CRQ2TH63M | NA | ||
ISOPROPYL PALMITATE | TRANSDERMAL | FILM | 142916 | 8CRQ2TH63M | 2mg | ||
ISOPROPYL PALMITATE | TRANSDERMAL | FILM, EXTENDED RELEASE | 142916 | 8CRQ2TH63M | 187.5mg | ||
ISOSTEARIC ACID | TOPICAL | CREAM | 30399849 | X33R8U0062 | 25%w/w | ||
ISOSTEARIC ACID | TOPICAL | GEL | 30399849 | X33R8U0062 | 20mg | Y | |
ISOSTEARIC ACID | TOPICAL | OINTMENT | 30399849 | X33R8U0062 | NA | ||
ISOSTEARYL ALCOHOL | TOPICAL | CREAM | 27458931 | Q613OCQ44Y | 3%w/w | ||
ISOSTEARYL ALCOHOL | TOPICAL | LOTION | 27458931 | Q613OCQ44Y | 100mg | ||
ISOSTEARYL ALCOHOL | TOPICAL | OINTMENT | 27458931 | Q613OCQ44Y | NA | ||
ISOSTEARYL ALCOHOL | TOPICAL | SUSPENSION | 27458931 | Q613OCQ44Y | 2.5%w/w | ||
ISOTONIC SODIUM CHLORIDE SOLUTION | EPIDURAL | INJECTION, SUSPENSION, LIPOSOMAL | VR5Y7PDT5W | 0.57%w/v | |||
ISOTONIC SODIUM CHLORIDE SOLUTION | INTRAMUSCULAR | INJECTION | VR5Y7PDT5W | 0.6%w/v | |||
ISOTONIC SODIUM CHLORIDE SOLUTION | INTRAVENOUS | INJECTION | VR5Y7PDT5W | 0.9%w/v | |||
ISOTONIC SODIUM CHLORIDE SOLUTION | INTRAVENOUS | SOLUTION | VR5Y7PDT5W | 1800mg |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 3, 2024
Database Last Updated: July 31, 2024